No specific pharmacological therapy (such as sulfonylureas used for KCNJ11 mutations [16]) is available for the initial phase of 6q24-TNDM-associated diabetes, but recognition of the etiology confirms that standard diabetes management is appropriate and that insulin can often be discontinued once remission is achieved. The gene discussed is KCNJ11; the disease is diabetes mellitus.